Skip to main content
. 2020 Jun 25;12(1):8642. doi: 10.4081/dr.2020.8642

Table 1.

The patients were divided into different groups based on the biotechnological or small molecular drug in use.

Ongoing therapy Number of patients Percentage of patients
Ustekinumab 61 25%
Etanercept 55 22%
Secukinumab 37 15%
Adalimumab 36 15%
Apremilast 22 9%
Ixekizumab 14 6%
Guselkumab 10 4%
Risankizumab 6 3%
Infliximab 3 1%
Brodalumab 1 0%
Certolizumab 1 0%